News

The Company has recent ly submi tted an application to the World Health Organization Pesticide Evaluation Scheme ( WHOPES ) for their recommendation on the product . SumiLarv

AgeneBio is developing AGB101, a Phase-3 ready candidate targeting a large unserved aMCI patient population. If approved, AGB101 will be the first and only therapeutic that targets hippocampus

The approved claims describe the device and components that are important for its function. As previously announced, Adamis acquired worldwide rights to the Taper DPI technology in all

"This is a significant milestone for our company," noted Karl Pinto, CEO of Goodwin Biotechnology. "We have been committed to investing in and advancing the field of Bioconjugation

Under the terms of a joint venture (JV) agreement between the parties, G-treeBNT will be responsible for conducting and funding all clinical trials and product development through approval

The company said that signaling components of the PI3K pathway are central regulators of cell proliferation, growth, differentiation, survival and angiogenesis. About 80% of tumor types have been

The approval is subject to certain conditions, which the two parties have agreed to undertake following completion of the proposed transaction. The three-way transaction includes GSK buying Novartis’

The API produced is expected to provide sufficient quantities of aramchol for Galmed’s potential future Phase III clinical trials of aramchol to treat Non-Alcoholic Steato-Hepatitis (NASH). As part

MN-001 exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE), and inhibition